

Supplemental Table 1. Types of toxicities with temozolomide-containing therapies

Toxicity Type	Details (cases)	N (times)	Number of patients with toxicity	Rate of toxicity occurrence (%)
Hematological system	Leukopenia (173), thrombocytopenia (100), neutropenia (76), anemia (55), lymphopenia (43), leukocytosis (25), eosinophilia granulocytosis (24), other (60)	556	275	29.83
Gastrointestinal system	Nausea (150), emesis (124), constipation (45), diarrhea (8), other (21)	348	195	21.15
Liver function	Increased alanine aminotransferase (130), increased aspartate aminotransferase (84), abnormal bilirubin (35), abnormal alkaline phosphatase (8), other (45)	302	139	15.08
Other	Dizziness (31), headache (28), loss of appetite (20), hair loss (19), fatigue (15), electrolyte disturbance (14), drowsiness (7), aphasia (3), others (69)	206	178	19.31

Supplemental Table 2. Univariate analysis of the body-mass index (BMI)

Variab	With toxicity	Without toxicity	Total (n=616)	χ^2	
	N (constituent ratio)	N (constituent ratio)	N (constituent ratio)	value	P-value
BMI				6.705	0.082
<18.5	37 (11.0%)	18 (6.4%)	55 (8.9%)		
18.5-23.9	175 (52.2%)	170 (60.5%)	345 (56.0%)		
24.0-27.9	101 (30.1%)	80 (28.5%)	181 (29.4%)		
>28.0	22 (6.6%)	13 (4.6%)	35 (5.7%)		

Supplemental Table 3. Multivariate analysis of factors affecting the occurrence of toxicities in the hematological system

Variable	B	Standard error	Wald	Significance	OR (95% CI)
----------	---	----------------	------	--------------	-------------

Chemotherapy regimen

Complex chemotherapy regimen	1.567	0.400	15.341	<0.001	4.790	(2.187-10.491)
Only as adjuvant chemotherapy after radiotherapy	1.670	0.687	5.912	0.015	5.313	(1.382-20.421)
Combined chemotherapy	0.528	0.344	2.356	0.125	1.696	(0.864-3.331)
Concurrent chemoradiotherapy with adjuvant chemotherapy	1.860	0.599	9.642	0.002	6.423	(1.986-20.780)
Mono-chemotherapy					Ref (1.00)	

Chemotherapy cycle

2	0.541	0.223	5.864	0.015	1.718	(1.109-2.662)
3	0.846	0.273	9.566	0.002	2.329	(1.363-3.980)
4	0.928	0.305	9.251	0.002	2.529	(1.391-4.597)
5	1.127	0.361	9.728	0.002	3.087	(1.520-6.269)

6	0.887	0.318	7.778	0.005	2.427 4.526)	(1.302-
7	0.927	0.414	5.004	0.025	2.527 5.691)	(1.122-
8 or more	1.790	0.422	17.954	<0.001	5.990 13.710)	(2.617-
1					Ref (1.00)	
<i>Clinical stage</i>						
Stage 1-2	-0.440	0.178	6.136	0.013	0.644 0.912)	(0.454-
Stage 3-4					Ref (1.00)	

OR: odds-ratio, CI: confidence-interval

Supplemental Table 4. Multivariate analysis of factors affecting the occurrence of toxicities in the gastrointestinal system

Variable	B	Standard error	Wald	Significance	OR (95% CI)
<i>Gender</i>					

Female	0.628	0.177	12.545	<0.001	1.875 (1.324-2.654)
Male					Ref (1.00)
<i>Age</i>					
<18	0.892	0.376	5.608	0.018	2.439 (1.166-5.101)
18-39	0.375	0.270	1.928	0.165	1.455 (0.857-2.469)
40-59	-0.158	0.239	0.435	0.509	0.854 (0.534-1.365)
>59					Ref (1.00)
<i>Clinical diagnosis</i>					
Lung cancer	1.826	0.581	9.881	0.002	6.207 (1.988-19.374)
Melanoma	0.671	0.604	1.234	0.267	1.956 (0.599-6.386)
Glioma	0.481	0.562	0.735	0.391	1.618 (0.538-4.864)
Lymphoma	0.601	0.676	0.791	0.374	1.825 (0.485-6.866)
Others	1.104	0.568	3.779	0.052	3.018 (0.991-9.190)
Neuroendocrine carcinoma					Ref (1.00)
<i>Clinical stage</i>					
Stage 1-2	-0.535	0.210	6.518	0.010	0.586 (0.388-0.883)

Stage 3-4	Ref (1.00)
-----------	------------

OR: odds-ratio, CI: confidence-interval

Supplemental Table 5. Multivariate analysis of factors affecting the occurrence of toxicities in the liver

Variable	B	Standard error	Wald	Significance	OR (95% CI)
<i>Age</i>					
<18	-2.363	1.045	5.114	0.024	0.094 (0.012-0.730)
18-39	0.035	0.304	.013	0.909	1.036 (0.571-1.879)
40-59	0.067	0.264	.065	0.798	1.070 (0.638-1.794)
>59					Ref (1.00)
<i>Clinical diagnosis</i>					
Glioma	1.110	0.693	2.567	0.109	3.034 (0.780-11.793)
Lung cancer	0.137	0.800	0.029	0.864	1.147 (0.239-5.497)

Melanoma	0.563	0.776	0.526	0.468	1.756 (0.384-8.033)
Lymphoma	1.793	0.752	5.678	0.017	6.007 (1.375-26.248)
Others	0.304	0.742	0.167	0.683	1.355 (0.316-5.805)
Neuroendocrine carcinoma					Ref (1.00)
Chemotherapy regimen					
Complex chemotherapy regimen	1.464	0.553	7.000	0.008	4.325 (1.462-12.798)
Only as adjuvant chemotherapy after radiotherapy	1.440	0.968	2.211	0.137	4.221 (0.633-28.162)
Combined chemotherapy	1.215	0.506	5.763	0.016	3.370 (1.250-9.0882)
Concurrent chemoradiotherapy with adjuvant chemotherapy	1.909	0.840	5.161	0.023	6.747 (1.300-35.033)
Mono-chemotherapy					Ref (1.00)

OR: odds-ratio, CI: confidence-interval

